What question did this study set out to answer?

To identify therapeutic variables and prognostic clinical factors associated with overall survival in patients treated for primary central nervous system lymphoma.

May 28, 2002Neurology

A multicenter study of treatment of primary CNS lymphoma

View Full Paper

Ask AI

Bookmark

Authors

AFAndrés J.M. FerreriSemmelweis University MRMichele ReniIRCCS Ospedale San Raffaele FPFelice PasiniUniversity of Verona

Discussion

Member takes

Implication

Multicenter study reveals improved survival with high-dose methotrexate chemotherapy in primary CNS lymphoma, indicating consolidation radiotherapy may be omitted after complete response.

Key Points

To identify therapeutic variables and prognostic clinical factors associated with overall survival in patients treated for primary central nervous system lymphoma.
Analyzed clinical outcomes across a multicenter cohort of 370 patients with primary central nervous system lymphoma over a median follow-up of 24 months.
Evaluated treatment sequencing: radiotherapy alone (n=98), chemotherapy alone (n=32), radiotherapy followed by chemotherapy (n=36), and chemotherapy followed by radiotherapy (n=197).
Compared specific therapeutic regimens, including high-dose methotrexate (1 to 8 g/m²; n=169) with or without additional cytostatics, and intrathecal chemotherapy (n=109).
Overall survival at 2 years was 37% (116 patients alive), with chemotherapy followed by radiotherapy producing significantly superior survival relative to radiotherapy alone.
Primary chemotherapy regimens containing high-dose methotrexate yielded longer survival than non-methotrexate regimens, with further survival gains seen when combined with high-dose cytarabine; methotrexate dose level did not correlate with survival.
Consolidation radiotherapy and intrathecal chemotherapy provided no survival benefit in patients treated with high-dose methotrexate, while age, performance status, LDH, and CSF protein independently predicted survival.

Cite This Study

Ferreri et al. (2002) studied this question.

synapsesocial.com/papers/69fd8f73f9b1bbfa2c271553 https://doi.org/10.1212/wnl.58.10.1513

View Full Paper

Ask AI

Bookmark

Implication

Multicenter study reveals improved survival with high-dose methotrexate chemotherapy in primary CNS lymphoma, indicating consolidation radiotherapy may be omitted after complete response.

A multicenter study of treatment of primary CNS lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

A multicenter study of treatment of primary CNS lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider